Interim report of the UKCLL02 trial: A phase II study of subcutaneous alemtuzumab plus fludarabine in patients with fludarabine refractory CLL (on behalf of the NCRI CLL trials sub-group).

被引：2

作者：

Sayala, H

Moreton, P

Richard, JA

Andy, RC

Sheila, O

Paul, E

Anthony, C

Claire, D

Estella, M

Andrew, PR

Daniel, KB

Peter, H

机构：

[1] Leeds Gen Infirm, Haematol Malignancy Diagnost Serv, Leeds, W Yorkshire, England

[2] Royal Liverpool Univ Hosp, Liverpool, Merseyside, England

[3] Canc Res Inst, London, England

[4] Leicester Royal Infirm, Leicester, Leics, England

来源：

关键词：

D O I：

10.1182/blood.V106.11.2120.2120

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

2120

引用

页码：599A / 600A

页数：2